Natpara

Natpara Uses, Dosage, Side Effects, Food Interaction and all others data.

Natpara (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa).

Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).

Natpara is responsible for the fine regulation of serum calcium concentration on a minute-to-minute basis. This is achieved by the acute effects of the hormone on calcium resorption in bone and calcium reabsorption in the kidney. The phosphate mobilized from bone is excreted into the urine by means of the hormone's influence on renal phosphate handling. Natpara also stimulates calcium absorption in the intestine, this being mediated indirectly by 1,25-dihydroxyvitamin D. Thus, a hypocalcemic stimulus of parathyroid hormone secretion results in an increased influx of calcium from three sources (bone, kidney, and intestine), resulting in a normalization of the serum calcium concentration without change in the serum phosphate concentration.

Natpara
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Natpara
Generic	Parathyroid hormone
Parathyroid hormone Other Names	Parathormone, Parathormone (human recombinant), Parathyrin, Parathyroid hormone, PTH
Weight	100mcg/dose, 25mcg/dose, 50mcg/dose, 75mcg/dose,
Type	Subcutaneous powder for injection
Formula	C₄₀₈H₆₇₄N₁₂₆O₁₂₆S₂
Weight	9420.0 Da
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States,
Last Updated:	September 19, 2023 at 7:00 am

Uses

Natpara is an analog of human parathyroid hormone (PTH) used to treat hypocalcemia caused by hypoparathyroidism.

For use/treatment in osteoporosis.

Natpara is also used to associated treatment for these conditions: Hypocalcemia, Hypoparathyroidism

How Natpara works

The biological actions of rhPTH are mediated through binding to at least two distinct high- affinity cell-surface receptors specific for the N-terminal and C-terminal regions of the molecule, both of which are required for normal bone metabolism. The N-terminal portion of the molecule is primarily responsible for the bone building effects of parathyroid hormone. The C-terminal portion of the molecule has antiresorptive activity and is necessary for normal regulation of N-terminal fragment activity.

Food Interaction

No interactions found.

Volume of Distribution

The volume of distribution at steady-state following intravenous administration is approximately 5.4 liters with an interpatient variability of about 40%.